Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS‐BRAF wild‐type colorectal cancer receiving cetuximab or panitumumab

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|137|6|1467-1474

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.137, Iss.6, 2015-09, pp. : 1467-1474

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Quality of life in patients with K‐RAS wild‐type colorectal cancer

By  

CANCER, Vol. 120, Iss. 2, 2014-01 ,pp. : 181-189

John Wiley & Sons Inc

Access to resources Recommend Favorite

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)

By Lawrence Donna   Maschio Michael   Leahy Kevin J.   Yunger Simon   Easaw Jacob C.   Weinstein Milton C.  

Journal of Medical Economics, Vol. 16, Iss. 12, 2013-12 ,pp. : 1387-1398

Informa Healthcare

Access to resources Recommend Favorite

Circulating Tumor Cells as a Potential Biomarker in Selecting Patients for Pulmonary Metastasectomy from Colorectal Cancer:Report of a Case

By  

Case Reports in Oncology, Vol. 5, Iss. 3, 2012-10 ,pp. : 542-545

Karger

Access to resources Recommend Favorite

Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma – A Report of Two Cases

By  

Case Reports in Oncology, Vol. 3, Iss. 2, 2010-05 ,pp. : 154-159

Karger

Access to resources Recommend Favorite

A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan

By  

Oncology, Vol. 84, Iss. 4, 2013-01 ,pp. : 210-213

Karger

Access to resources Recommend Favorite